Exchange Traded Concepts LLC Sells 21,072 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Exchange Traded Concepts LLC reduced its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 91.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,007 shares of the biopharmaceutical company’s stock after selling 21,072 shares during the period. Exchange Traded Concepts LLC’s holdings in Catalyst Pharmaceuticals were worth $40,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Pacer Advisors Inc. increased its position in shares of Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after acquiring an additional 2,965,310 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Catalyst Pharmaceuticals by 139.5% in the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after purchasing an additional 1,587,794 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after buying an additional 860,244 shares during the period. Mesirow Institutional Investment Management Inc. bought a new position in shares of Catalyst Pharmaceuticals during the first quarter worth about $11,463,000. Finally, Kennedy Capital Management LLC raised its position in Catalyst Pharmaceuticals by 101.1% in the 1st quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company’s stock valued at $16,924,000 after buying an additional 533,802 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. HC Wainwright raised their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Citigroup lifted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $29.50.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the transaction, the insider now directly owns 12,369 shares in the company, valued at $227,836.98. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now directly owns 12,369 shares in the company, valued at approximately $227,836.98. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 201,058 shares of company stock valued at $4,018,188 in the last quarter. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $21.34 on Thursday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.89 and a 52-week high of $21.85. The company has a market capitalization of $2.52 billion, a P/E ratio of 39.52, a price-to-earnings-growth ratio of 3.18 and a beta of 0.76. The company has a 50-day simple moving average of $20.31 and a 200 day simple moving average of $17.53.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The company had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. As a group, equities analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.